News | March 04, 2021
Merck FY20 sales up 8.6% euro 17.5 bn
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
ranules now has a total of 38 ANDA approvals from US FDA.
India business grew 11.8% YoY vs mid-single digit industry growth.
The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse
According to IQVIA sales data for the 12 month period ending December 2020, the Cleocin T Gel, 1% market achieved annual sales of approximately $73.8 million.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
Subscribe To Our Newsletter & Stay Updated
